Upadacitinib: all 94 studies that test it

Page 1 of 1. Open to participants first (34), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingNCT07843693Phase 1
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingNCT07772492Phase 3
• A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingNCT07770646Phase 4
• Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance DoseNot yet recruitingNCT07700446Phase 4
• The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe ItchingNot yet recruitingNCT07678645Phase 2
• Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating MutationsNot yet recruitingNCT07670156Phase 1/2
• A Trial of Upadacitinib for Non-responsive Eosinophilic EsophagitisRecruitingNCT07588568Phase 2
• Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）RecruitingNCT07550673Phase 4
• Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）RecruitingNCT07546097Phase 4
• TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingNCT07510191Phase 4
• Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative ColitisNot yet recruitingNCT07502339Phase 4
• Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.RecruitingNCT07492251Phase 2
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative ColitisRecruitingNCT07258771Phase 4
• Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyNot yet recruitingNCT07149467Phase 3
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT07064889Phase 2
• Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial SpondyloarthritisNot yet recruitingNCT07018206Phase 4
• Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug StudyRecruitingNCT06928272Phase 3
• Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's DiseaseRecruitingNCT06902987Phase 1
• Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing PolychondritisRecruitingNCT06873100Phase 1/2
• Therapeutic Effect of Upadacitinib in Primary Sjögren's SyndromeNot yet recruitingNCT06862284Phase 2
• JAK Inhibitor Dose TAPering Strategy StudyRecruitingNCT06687551Phase 4
• Upadacitinib as a Novel Treatment for Refractory Eyelid DermatitisRecruitingNCT06684522Early Phase 1
• Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative ColitisRecruitingNCT06660693Phase 3
• Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's DiseaseRecruitingNCT06520397Phase 4
• Efficacy of Upadacitinib After NECS in VitiligoRecruitingNCT06454461Not applicable
• A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic ArthritisRecruitingNCT06454188Phase 4
• Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult SubjectsRecruitingNCT06379958Phase 1
• A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingNCT06227910Phase 3
• Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative ColitisRecruitingNCT06095596Not applicable
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataRecruitingNCT06012240Phase 3
• Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative ColitisRecruitingNCT05867329Phase 4
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
• A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05601882Phase 3Results posted
• A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05507580Phase 4Results posted
• Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental VitiligoCompletedNCT04927975Phase 2Results posted
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateCompletedNCT04451772Phase 2Results posted
• A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsCompletedNCT04430855Phase 2Results posted
• Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT04195698Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial SpondyloarthritisCompletedNCT04169373Phase 3Results posted
• A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)CompletedNCT03978520Phase 2Results posted
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibTerminatedNCT03823378Phase 2Results posted
• A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03738397Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisCompletedNCT03725202Phase 3Results posted
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisCompletedNCT03682705Phase 2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)CompletedNCT03607422Phase 3Results posted
• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)CompletedNCT03569293Phase 3Results posted
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruitingNCT03568318Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic TherapiesCompletedNCT03345849Phase 3Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyCompletedNCT03345836Phase 3Results posted
• A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing SpondylitisCompletedNCT03178487Phase 2Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)CompletedNCT02955212Phase 3Results posted
• A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisCompletedNCT02925117Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCompletedNCT02782663Phase 2Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsCompletedNCT02720523Phase 2/3Results posted
• A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateCompletedNCT02706873Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT02706847Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneCompletedNCT02675426Phase 3Results posted
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyCompletedNCT02365649Phase 2Results posted
• A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneCompletedNCT02066389Phase 2Results posted
• An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisCompletedNCT02049138Phase 2Results posted
• A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyCompletedNCT01960855Phase 2Results posted
• An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory UveitisActive, not recruitingNCT07773623Phase 4
• A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis SuppurativaActive, not recruitingNCT07727889Phase 2
• A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult ParticipantsCompletedNCT07425899Phase 1
• Upadacitinib for Refractory Behcet's SyndromeCompletedNCT07080346Phase 2
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataActive, not recruitingNCT07023302Phase 3
• Upadacitinib for Prurigo NodularisTerminatedNCT06773403Phase 4
• Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMFCompletedNCT06758947Phase 3
• Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06701331Phase 3
• A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisWithdrawnNCT06390722Phase 3
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingNCT06389136Phase 3
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT06332534Phase 3
• A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With VitiligoActive, not recruitingNCT06118411Phase 3
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive, not recruitingNCT05889182Phase 3
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusActive, not recruitingNCT05843643Phase 3
• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT05814627Phase 3
• Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.Active, not recruitingNCT05782907Phase 3
• Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.Status unknownNCT05153200Phase 4
• Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus MethotrexateStatus unknownNCT05121298Phase 3
• COVID-19 VaccinE Response in Rheumatology PatientsCompletedNCT05080218Phase 4
• A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in BrazilWithdrawnNCT04666675Phase 3
• A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Phase 3
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic ArthritisActive, not recruitingNCT03725007Phase 1
• A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03661138Phase 3
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic DermatitisCompletedNCT03646604Phase 1
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433Active, not recruitingNCT03345823Phase 3
• A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
• A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494CompletedNCT01741493Phase 1

← Upadacitinib overview